Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-05-14

Study Completion Date

2015-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is to compare the score to the Behavioral Dysexecutive Syndrome Inventory (BDSI) between Parkinsonian Multiple system Atrophy MSA-P patients and cerebellar Multiple System Atrophy (MSA-C) patients matched on disease duration, age (± 7 years) and sex .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy

NCT01577992

Pain Threshold Multiple System Atrophy

COMPLETED NA

Clinical Outcome Study for Dysferlinopathy

NCT01676077

Dysferlinopathy LGMD2B Now Classified as LGMDR2 Miyoshi Myopathy

UNKNOWN

Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study

NCT01044992

Multisystemic Atrophy

COMPLETED NA

Predicting Cognition After DBS for Parkinson's Disease 2

NCT06272968

Cognitive Impairment

ACTIVE_NOT_RECRUITING

A Retrospective Study of the Relationship Between White Matter Hyperintensities(WMHs) Within the Cholinergic Pathways and the Cognition of PD Patients After Bilateral STN DBS

NCT02071693

Parkinson's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple system atrophy (MSA) is a rare neurodegenerative disorder which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. According to the consensus criteria for the diagnosis of MSA, the presence of dementia is considered an exclusion criteria. However, several studies have reported cognitive impairment in patients with MSA, dominated by a dysexecutive syndrome. Some studies have compared the cognitive profile of MSA-P patients and MSA-C but any have studied the behavioral dysexecutive syndrome in this population. In 2010, the GREFFEX has established criteria for dysexecutive syndrome and described two distinct parts: the dysexecutive syndrome and cognitive behavioral dysexecutive syndrome. Our clinical impression is that according to the type of MSA, the dysexecutive syndrome seems to be different : the MSA-P patients seem to have a cognitive dysexecutive syndrome and the MSA-C patients a behavioral dysexecutive syndrome.

We want to compare the BDSI score between MSA-P patients and MSA-C patients matched on disease duration, age and sex The specific involvement of the cerebellum in behavioral disorders could explain the behavioral differences experienced by clinicians caring for these patients but never demonstrated. The presence of these disorders could have an impact on the relationship between the patient and the caregiver. In addition, few studies have correlated with cognitive imagery data. Therefore, the exact areas involved in cognitive and behavioral MSApatients remain poorly understood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple System Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MSA-P

Clinical evaluation

Intervention Type OTHER

neuropsychological battery test

Intervention Type OTHER

MRI

Intervention Type OTHER

Actigraphy

Intervention Type OTHER

Actigraphy recording will be performed during 7 days after inclusion.

MSA-C

Clinical evaluation

Intervention Type OTHER

neuropsychological battery test

Intervention Type OTHER

MRI

Intervention Type OTHER

Actigraphy

Intervention Type OTHER

Actigraphy recording will be performed during 7 days after inclusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical evaluation

Intervention Type OTHER

neuropsychological battery test

Intervention Type OTHER

MRI

Intervention Type OTHER

Actigraphy

Actigraphy recording will be performed during 7 days after inclusion.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suffering from "probable" MSA according to clinical consensus criteria (Gilman et al, 2008),
* Age \>30
* Written informed consent
* Patient covered by the national health system
* The presence of an informant
* Blood negative dosage of the hormone béta-hCG for the women old enough to procreate

Exclusion Criteria

* UMSARS IV score \> 4 points
* Pregnant woman (blood positive dosage of the hormone béta-hCG) or breast feeding
* Patient under tutelage
* Patient unable to give consent
* Against indication to perform an MRI

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No